- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Ipca Labs to Shut Mahad Drug Intermediates Unit, Sell Property for Rs 16.90 Crore

Mumbai: Ipca Laboratories Limited has decided to close the manufacturing operations of its drug intermediates manufacturing unit at Mahad, Maharashtra, and transfer the leasehold land and existing factory buildings to ICMC Corporation Limited for a consideration of Rs 16.90 crore, subject to necessary approvals.
In a regulatory filing, the pharmaceutical company stated that the decision is part of its operational strategy to optimise manufacturing facilities, reduce the number of manufacturing units and minimise operational and other costs.
The property proposed to be transferred comprises leasehold Plot Nos. C-89 to C-95 at MIDC, Mahad, Maharashtra. The leasehold land measures approximately 25,138 square metres, while the old factory buildings, structures and sheds standing on the property cover approximately 11,913 square metres. The transaction includes the transfer of all rights, title and interest in the leasehold land, along with the existing structures.
Ipca Laboratories stated that the plant and machinery located at the Mahad unit will be transferred to its other manufacturing facilities. The drug intermediates previously manufactured at the unit have also been shifted to other manufacturing units of the company.
The Mahad facility was primarily engaged in manufacturing drug intermediates, most of which were used captively for the company's active pharmaceutical ingredient (API) manufacturing operations. The current written-down value of the leasehold land and old buildings, structures and sheds at the facility stands at Rs 13.21 crore.
The company clarified that the closure of the manufacturing unit and the proposed sale of the property will not have any impact on its business or financials. It also stated that the transaction will not result in any change in the company's shareholding pattern.
Ipca Laboratories has entered into a memorandum of understanding (MoU) with ICMC Corporation Limited on November 20, 2026. The final transaction deed will be executed in due course, subject to the required approvals and consents. The sale is expected to be completed on or before March 31, 2027, or on another date mutually agreed upon, subject to approval from the Maharashtra Industrial Development Corporation (MIDC) for the transfer of leasehold rights.
ICMC Corporation Limited is engaged in the development, manufacture, distribution and sale of micronutrient fertilisers. The company clarified that ICMC Corporation does not belong to the promoter or promoter group and is not a related party. The consideration of Rs 16.90 crore will be paid through bank transfers.
The transaction does not fall within the purview of related-party transactions and is outside the scheme of arrangement. Ipca Laboratories stated that the proposed sale is in compliance with Regulation 37A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations.
Ipca Laboratories is engaged in the development, manufacturing, marketing and distribution of pharmaceutical products. The company stated that the proposed closure and property transfer form part of its ongoing initiative to optimise manufacturing facilities and reduce the number of smaller manufacturing units.
M. Pharm (Pharmaceutics)
Parthika Patel has completed her Graduated B.Pharm from SSR COLLEGE OF PHARMACY and done M.Pharm in Pharmaceutics. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751

